Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
30.76
+0.13 (0.41%)
Nov 21, 2024, 10:54 AM EST - Market open
Akero Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
56
Market Cap
2.15B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Astrana Health | 1.72B |
Addus HomeCare | 1.13B |
Omnicell | 1.06B |
Evotec SE | 866.67M |
Amphastar Pharmaceuticals | 723.55M |
Mirum Pharmaceuticals | 307.03M |
GeneDx Holdings | 267.23M |
Ligand Pharmaceuticals | 152.42M |
AKRO News
- 5 days ago - Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 7 days ago - Akero Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 13 days ago - Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 7 weeks ago - INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - PRNewsWire
- 7 weeks ago - Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference - GlobeNewsWire
- 2 months ago - Akero Therapeutics: Good Candidate For The MASH Basket - Seeking Alpha
- 2 months ago - Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH - GlobeNewsWire